Abstract
Biological age acceleration (BAA) models based on blood tests or DNA methylation emerge as a de facto standard for quantitative characterizations of the aging process. We demonstrate that deep neural networks trained to predict morbidity risk from wearable sensor data can provide a high-quality and cheap alternative for BAA determination. The GeroSense BAA model presented here was tolerant of gaps in the data, and exhibited a superior association with life-expectancy over the average number of steps per day, e.g., in groups stratified by professional occupations. The association between the BAA and effects of lifestyles, the prevalence or future incidence of diseases was comparable to that of BAA from models based on blood test results. Wearable sensors let sampling of BAA fluctuations at time scales corresponding to days and weeks and revealed the divergence of organism state recovery time (resilience) as a function of chronological age. The number of individuals suffering from the lack of resilience increased exponentially with age at a rate compatible with Gompertz mortality law. We speculate that due to stochastic character of BAA fluctuations, its mean and auto-correlation properties together comprise the minimum set of biomarkers of aging in humans.
Competing Interest Statement
P.O. Fedichev is a shareholder of Gero PTE. T.V. Pyrkov, I.S. Sokolov, P.O. Fedichev are employees of Gero PTE.
Funding Statement
This work was funded by Gero PTE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol for this study was reviewed by the ethics committee of the Institute of Clinical Pharmacology, Smolensk, Russia and approval was given (study registration number G-099, protocol 52, 2016-04-29). The ethics committee board chair is Vladimir V. Rafalsky, the secretary of the ethics committee is Evgeny V. Dovgan. The data accessed for this study contained only anonymized, non-personally identifiable information. Gero app users were made aware and consented electronically to that their de-identified data could potentially be used for research in the app Privacy Policy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Correction: Figure 5 was mistakenly a duplicate of Figure 4. Now corrected and inserted Figure 5.
Data Availability
The data that support the findings of this study is available upon reasonable request from the authors.
